上万元一支的面部“骨性生物支架”火遍小红书 还有这些坑需要避

Core Viewpoint - Social media has become the primary information source for young cosmetic consumers, with a growing interest in calcium hydroxyapatite (CaHA) as a regenerative injectable material, often referred to as the "hardest hyaluronic acid" [1] Market Overview - Hyaluronic acid currently holds a dominant 77% market share in the global dermal filler market, while calcium hydroxyapatite accounts for 7% [1] - Merz Aesthetics' Radiesse is the only FDA-approved calcium hydroxyapatite facial filler in the global market, recently approved in China [2] - Domestic companies such as Haohai Biological Technology, Huaxi Biological, and Juzhi Biological are actively developing calcium hydroxyapatite products, intensifying market competition [2] Regulatory and Safety Concerns - Only two calcium hydroxyapatite products are approved for facial injection in China, highlighting the limited scope of approved applications [2] - The use of calcium hydroxyapatite in cosmetic procedures is subject to strict regulatory oversight, requiring clinical trials for injectable products, which can take 6 to 7 years for approval [4] - There are concerns regarding the misuse of calcium hydroxyapatite products, with reports of unqualified products being injected in medical aesthetic clinics [2][4] Consumer Awareness and Risks - The medical aesthetic market faces challenges with misleading advertising and the promotion of unapproved products, leading to potential consumer harm [6] - Experts emphasize the importance of consumers verifying the legitimacy of products and the qualifications of practitioners before undergoing treatments [5][6] - The industry is marked by a disconnect between regulatory bodies, manufacturers, and medical aesthetic institutions, complicating compliance and consumer safety [4]